What Are the Clinical Implications?
coronary artery disease, thrombocytopenia, chronic coronary syndromes, bleeding
BLEEDING, THROMBOCYTOPENIA, THROMBOCYTOPENIA, CORONARY ARTERY DISEASE, EVENTS, EVENTS, ATRIAL FIBRILLATION, CORONARY ARTERY DISEASE, COMPLICATIONS

The findings of this study could serve as a reference for clinicians in planning approaches for antithrombotic therapy in patients with thrombocytopenia with CCS and AF.To further investigate the efficacy and safety of earlier de‐escalation to rivaroxaban monotherapy after coronary intervention for patients with AF and CCS, well‐designed, randomized controlled trials are necessary.Thrombocytopenia is rare but is an important risk factor for bleeding and ischemic complications in patients receiving drug‐eluting stent and dual antiplatelet therapy.The AFIRE (Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease) trial included patients diagnosed with AF and chronic coronary syndromes (CCS) >1 year after revascularization or those with angiographically confirmed coronary artery disease not requiring revascularization.This post hoc analysis of the AFIRE trial aimed to investigate the association between thrombocytopenia with an increased risk of major bleeding and cardiovascular events in patients with both AF and CCS. The relationship between the presence or absence of thrombocytopenia and the antithrombotic regimen on the clinical outcome of patients has also been investigated.